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progressive subcutaneous 1.2 by 1.2 cm swelling on the left upper
arm (Fig. 1a). On the same site, 0.1 mL Bacille Calmette-Guérin
(BCG) vaccine had been provided intradermally on the day of birth.
Manufactured by Queen Saovabha Memorial Institute, Thai Red
Cross Society, Bangkok, Thailand (Lot No. FB00817), 1 mL contains
about 2 million viable bacteria of the live attenuated Mycobac-
terium bovis Tokyo 172 strain. No systemic symptoms were
reported and on examination, no lymphadenitis was present. A
wait-and-see treatment approach was adopted, the infant was dis-
charged home, and a local health care worker documented the
spontaneous resolution of the lesion and the natural course of
healing (Fig. 1b–d).
BCG vaccines have been used for nearly a century, are consid-
ered safe and remain recommended by a majority of countries
[1]. Approximately 1–10% experience adverse reactions, of which
most are localised (i.e. abscess, lymphadenitis); systemic adverse
reactions (e.g. osteomyelitis, BCG disease) are rarely observed [2].
Adapting a conservative wait and see approach for localized BCGinjection site reactions as well as non-suppurative lymphadenitis,
leads to a self-limiting, spontaneous resolution of symptoms in
the majority of cases.Acknowledgements
The Shoklo Malaria Research Unit is part of the Wellcome Trust
Mahidol University Oxford Tropical Medicine Research Programme
supported by the Wellcome Trust of Great Britain.References
[1] Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The
efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the
prevention of tuberculosis: meta-analyses of the published literature. Pediatrics
1995;96(1 Pt 1):29–35.
[2] Venkataraman A, Yusuff M, Liebeschuetz S, Riddell A, Prendergast AJ.
Management and outcome of Bacille Calmette-Guérin vaccine adverse
reactions. Vaccine 2015;33(41):5470–4.
